Characterization of Cannabis Products Purchased for Medical Use in New York State

Abstract

sample of patients who made 2 or more purchases of a medical cannabis product. d This sample reflects data reported in the Medical Use of Marijuana Under the Compassionate Care Act Two Year Report. e Conditions are not mutually exclusive; therefore, percentages may total more than 100%. f Opioid replacement was not an approved qualifying condition for medical cannabis use during the study period. Author affiliations and article information are listed at the end of this article.

Nationally representative surveys on cannabis use lack product details relevant to public health

“…As more US states legalize medical and adult cannabis use, the range of cannabis products, consumption modes, and tetrahydrocannabinol (THC) and cannabidiol (CBD) potencies has expanded ( Hasin et al., 2016 ; Kritikos and Pacula, 2022 ), introducing variation in cannabis use behaviors and related health implications. For example, self-reported therapeutic benefits and side effects vary with product, consumption mode, and potency ( Stith et al., 2019 ).…”